bill ordering a state study of psychedelic therapies

The text as introduced · 401 words

89R11615 MCF-D

By: Blanco
S.B. No. 3005

A BILL TO BE ENTITLED

AN ACT

relating to a study on the use of psychedelic therapies in the

treatment of certain conditions.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:

SECTION 1. (a) In this Act:

(1) "Department" means the Department of State Health

Services.

(2) "Psychedelic therapies" means the use of

3,4-methylenedioxymethamphetamine (MDMA), psilocybin, or ketamine

to treat mental health or other medical conditions.

(b) The department, in consultation with Baylor College of

Medicine and the Center for Psychedelic Research and Therapy at

Dell Medical School at The University of Texas at Austin, shall

conduct a study on the use of psychedelic therapies for treatment of

post-traumatic stress disorder, depression, and other co-occurring

conditions.

(c) In conducting the study, the department shall:

(1) review clinical trials on the efficacy of using

psychedelic therapies in the treatment of post-traumatic stress

disorder, depression, and other co-occurring conditions;

(2) review current literature regarding the use of

psychedelic therapies in the treatment of post-traumatic stress

disorder, depression, and other co-occurring conditions;

(3) review actions of the United States Food and Drug

Administration regarding psychedelic therapies for treatment of

post-traumatic stress disorder, depression, and other co-occurring

conditions;

(4) evaluate treatment guidelines for use of

psychedelic therapies to treat post-traumatic stress disorder,

depression, and other co-occurring conditions and recommend

guidelines and best practices for providers; and

(5) evaluate patient access to current treatment for

post-traumatic stress disorder, depression, and other co-occurring

conditions and recommend legislative or other actions necessary to

ensure patient access to psychedelic therapies following approval

by the United States Food and Drug Administration, including

considerations of provider availability, affordability,

accessibility, training and licensure, and other regulatory

requirements.

(d) Not later than December 1, 2026, the department shall

submit to the governor, the lieutenant governor, the speaker of the

house of representatives, and the chair of the standing committee

of each house of the legislature with primary jurisdiction over the

department a written report that includes:

(1) the results of the study conducted under this

section; and

(2) any recommendations for legislative or other

action necessary to ensure patient access to psychedelic therapies

for treatment of post-traumatic stress disorder, depression, and

other co-occurring conditions after those therapies are approved by

the United States Food and Drug Administration.

(e) This Act expires September 1, 2027.

SECTION 2. This Act takes effect September 1, 2025.